Is Prolonged Daratumumab Maintenance Useful in Light-Chain Amyloidosis?

Daratumumab-based therapy is a cornerstone of treatment for light-chain (AL) amyloidosis; however, the optimal treatment duration remains undefined. We retrospectively analyzed 399 newly diagnosed AL amyloidosis patients treated at 2 centers according to center-specific planned daratumumab treatment durations (12 vs ≥ 24 cycles). Overall survival (OS), cumulative incidence of next treatment, and organ responses were compared using an intention-to-treat approach. A separate cohort of 184 relapsed/refractory patients was similarly analyzed. The 12- and ≥ 24-cycle cohorts included 181 and 218 patients, respectively. OS and cumulative incidence of next treatment were comparable between groups (P = 0.639 and P = 0.336, respectively), including among patients aged ≥ 65 years and those with bone marrow plasma cell ≥ 10%. Extended treatment increased the 24-month rate of renal responses ≥very good partial response (42% vs 26%; P = 0.023) but did not improve cardiac responses. Similar findings were observed in relapsed/refractory patients, with better renal responses but no OS or next-treatment benefit. Overall, treatment beyond 12 cycles was not associated with statistically significant improvements in OS or a lower cumulative incidence of next treatment, although clinically meaningful effects cannot be excluded. Prospective studies are needed to clarify the potential benefits of prolonged daratumumab treatment in AL amyloidosis.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11583799/v1
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Is Prolonged Daratumumab Maintenance Useful in Light-Chain Amyloidosis?

Mario Nuvolone, Marco Basset, Shen Kai-ni, Claudia Bellofiore et al.
2 links
Research Square
Amyloidosis: Diagnosis, Treatment, Outcomes
preprint

Is Prolonged Daratumumab Maintenance Useful in Light-Chain Amyloidosis?

Mario Nuvolone, Marco Basset, Shen Kai-ni, Claudia Bellofiore, Giovanni O. Palladini, Paolo Milani, Jian Li, Chengyang Xu, Ai Guan, Yi Xu
preprint en

Abstract

Daratumumab-based therapy is a cornerstone of treatment for light-chain (AL) amyloidosis; however, the optimal treatment duration remains undefined. We retrospectively analyzed 399 newly diagnosed AL amyloidosis patients treated at 2 centers according to center-specific planned daratumumab treatment durations (12 vs ≥ 24 cycles). Overall survival (OS), cumulative incidence of next treatment, and organ responses were compared using an intention-to-treat approach. A separate cohort of 184 relapsed/refractory patients was similarly analyzed. The 12- and ≥ 24-cycle cohorts included 181 and 218 patients, respectively. OS and cumulative incidence of next treatment were comparable between groups (P = 0.639 and P = 0.336, respectively), including among patients aged ≥ 65 years and those with bone marrow plasma cell ≥ 10%. Extended treatment increased the 24-month rate of renal responses ≥very good partial response (42% vs 26%; P = 0.023) but did not improve cardiac responses. Similar findings were observed in relapsed/refractory patients, with better renal responses but no OS or next-treatment benefit. Overall, treatment beyond 12 cycles was not associated with statistically significant improvements in OS or a lower cumulative incidence of next treatment, although clinically meaningful effects cannot be excluded. Prospective studies are needed to clarify the potential benefits of prolonged daratumumab treatment in AL amyloidosis.

Research Square
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), University of Pavia (IT), Peking Union Medical College Hospital (CN), Policlinico San Matteo Fondazione (IT)
European Commission, National Natural Science Foundation of China, Fondazione Cariplo, Peking Union Medical College Hospital, NextGenerationEU
Good health and well-being
Amyloidosis: Diagnosis, Treatment, Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon